Skip to search formSkip to main contentSkip to account menu

bosutinib

Known as: 4-Anilino-3-quinolinecarbonitrile, 4-Anilinobenzo(g)quinoline-3-carbonitrile, 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile 
A synthetic quinolone derivative and dual kinase inhibitor that targets both Abl and Src kinases with potential antineoplastic activity. Unlike… 
National Institutes of Health

Related topics

Related topics

13 relations

Broader (3)

Aniline CompoundsNitrilesQuinolines

Narrower (3)

BosulifBosutinib monohydrateSKI-606
Inhibition of Cell ProliferationNCIt Antineoplastic Agent TerminologyPositive Regulation of ApoptosisReceptor Protein-Tyrosine Kinases

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Effectiveness of Bosutinib in Chronic Myeloid Leukemia (CML) Who Have Received Multi Tyrosine Kinase Inhibitors (TKIs)
Background: Despite the general efficacy of tyrosine kinase inhibitors (TKIs) in the treatment of patients (pts) with chronic… 
2017
2017
Assessment of a potential therapeutic target in the Hedgehog pathway for the eradication of primitive chronic myeloid leukemia cells
..................................................................................................ii Lay Summary… 
2017
2017
New Guidelines Allow Some Patients With Chronic Myeloid Leukemia To Go Off Treatment.
2014
2014
BCR-ABL Point Mutations and TKI Treatment in CML Patients
Most newly diagnosed CML patients in the Chronic Phase (CP), when treated with imatinib, achieve durable responses. However, a… 
2014
2014
Erratum: Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors (Blood (2014) 123:9 1309-1318))
2010
2010
Safety and efficacy of third-line bosutinib in imatinib (IM) and dasatinib (DAS) resistant or intolerant chronic phase (CP) chronic myeloid leukemia (CML).
6514 Background: Bosutinib (SKI-606) is an oral Src/Abl kinase inhibitor, evaluated in an ongoing phase I/II study in CML… 
2009
2009
Inibidores de tirosino quinase na leucemia mieloide crônica
A leucemia mieloide cronica (LMC) e uma neoplasia da medula ossea originada da translocacao entre os cromossomos 9 e 22 t(9:22… 
2009
2009
New drugs to overcome meccanisms of resistance in Ph+ leukemia: bosutinib
The outcome for adult with Ph+ leukemias (ALL and CML) has improved dramatically with current therapy including use of Tyrosine… 
2008
2008
Hématologie maligne
En hématologie maligne, les scoops sont, en général, réservés au congrès de l’ASH en décembre, mais l’ASCO, en juin, fournit une… 
2006
2006
4-anilino-3-quinolinecarbonitrile for the treatment of cancer
A Chemical sensitivity of pancreatic adenocarcinoma for gemcitabine sought to determine the effect of expression suppression of c…